BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Potential Expansion of ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently received the CE-IVD approval (European certification) of its 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”). The approval facilitated initial sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East and North America. The company also recently announced delivery of 2,000 units of Covid-ID Lab to an established medical distributor in Israel. This, subject to commercial regulatory approval and subsequent potential product distribution, signaled XPhyto’s entry into the Middle East. “These units will be used for clinical evaluation based on the European CE-IVD approval, one of several international medical device certifications recognized by the Israeli government,” reads a recent article. “The evaluation, expected to be completed within 90 days, will be conducted by the Medical Device Division of the Israeli Ministry of Health (‘AMAR’). ‘We are excited by the opportunity to expand potential distribution beyond Germany,’ said CEO Hugh Rogers. ‘We are building strong partnerships around the world, and Israel is a leading nation for COVID-19 management and research.’”

To view the full article, visit https://ibn.fm/kyltV

About XPhyto Therapeutics Corp.

XPhyto Therapeutics works with the most promising disrupters in the pharmaceutical industry; accelerates research and technology development; and commercializes products with an entrepreneurial approach and a commitment to efficiency, effectiveness and accessibility. The company’s network spans Europe and North America, with companies at the forefront of diagnostics and drug formulations, and universities specializing in research on the use of psychedelics and cannabinoids. To learn more, visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF 

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork